<DOC>
	<DOCNO>NCT00726453</DOCNO>
	<brief_summary>The objective study assess safety effectiveness Resolute Zotarolimus-Eluting Coronary Stent System treatment de novo lesion native coronary artery reference vessel diameter ( RVD ) 2.25 mm 4.2 mm .</brief_summary>
	<brief_title>The Medtronic RESOLUTE US Clinical Trial</brief_title>
	<detailed_description>The trial comprise four study : 2.25 mm - 3.5 mm main study ( 1242 patient ) , 2.25 mm - 3.5 mm Angio/IVUS sub-study ( 100 patient ) , 4.0 mm sub-study ( 60 patient ) , 38 mm Length Sub-study ( 114 patient ) . A patient 's inclusion give study dependent size ( diameter length ) stent ( ) patient receives .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>General Angiographic Inclusion Criteria highlight : Acceptable candidate percutaneous coronary intervention ( PCI ) , stenting , emergency coronary artery bypass graft surgery Clinical evidence ischemic heart disease , stable unstable angina , silent ischemia and/or positive functional study Informed consent Patient agree comply specify followup evaluation investigational site Single target lesion two target lesion locate separate coronary artery De novo lesion ( ) native coronary artery ( y ) Target lesion ( ) ≤ 27 mm length ( ≤ 35 mm lesion treat 38 mm length stent ) Target vessel ( ) reference vessel diameter 2.25 mm 4.2 mm , ( 3.0 4.2 mm treat 38 mm length stent ) General Angiographic Exclusion Criteria highlight : Within 7 day implant platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ ; WBC count &lt; 3,000 cells/mm³ ; serum creatinine level &gt; 2.5 mg/dl Acute MI within 72 hrs index procedure ( QWMI elevation CKMB &gt; lab upper limit normal ) Previous PCI target vessel ( ) within 9 month prior procedure Planned PCI vessel within 30 day postindex procedure and/or plan PCI target vessel ( ) within 12 month postindex procedure History stroke TIA within prior 6 month Participating investigational drug/device study complete primary endpoint interferes study endpoint Inability comply require trial antiplatelet regimen Previous stent target vessel unless least 9 month since stent place target lesion ( ) is/are least 15 mm previous stent Target vessel ( ) has/have lesion w/ &gt; 40 % diameter stenosis Unprotected leave main coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>TARGET VESSEL REVASCULARIZATION ( TVR )</keyword>
	<keyword>MYOCARDIAL INFARCTION ( MI )</keyword>
	<keyword>TARGET VESSEL FAILURE ( TVF )</keyword>
	<keyword>TARGET LESION REVASCULARIZATION ( TLR )</keyword>
	<keyword>TARGET LESION FAILURE ( TLF )</keyword>
	<keyword>STENT THROMBOSIS</keyword>
	<keyword>RESTENOTIC LESION</keyword>
	<keyword>PERCUTANEOUS CORONARY INTERVENTION ( PCI )</keyword>
</DOC>